Dolby Laboratories (DLB)
(Delayed Data from NYSE)
$79.20 USD
-0.71 (-0.89%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $79.26 +0.06 (0.08%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Dolby Laboratories falls in the month of September.
All items in Millions except Per Share data.
9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 957 | 818 | 1,272 | 1,127 | 925 |
Receivables | 262 | 244 | 233 | 180 | 189 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 36 | 24 | 11 | 26 | 32 |
Other Current Assets | 233 | 226 | 245 | 214 | 235 |
Total Current Assets | 1,488 | 1,311 | 1,761 | 1,547 | 1,382 |
Net Property & Equipment | 482 | 513 | 534 | 542 | 537 |
Investments & Advances | 98 | 103 | 63 | 52 | 180 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 202 | 184 | 156 | 119 | 114 |
Intangibles | 576 | 477 | 464 | 489 | 516 |
Deposits & Other Assets | 95 | 55 | 61 | 91 | 93 |
Total Assets | 2,980 | 2,690 | 3,106 | 2,917 | 2,822 |
Liabilities & Shareholders Equity | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 21 | 14 | 18 | 13 | 15 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 351 | 230 | 263 | 220 | 268 |
Income Taxes Payable | 5 | 1 | 1 | 3 | 4 |
Other Current Liabilities | 32 | 19 | 18 | 15 | 20 |
Total Current Liabilities | 422 | 278 | 316 | 267 | 307 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 148 | 123 | 129 | 147 | 202 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 608 | 439 | 501 | 479 | 509 |
Shareholders Equity | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | 2,392 | 2,298 | 2,608 | 2,443 | 2,328 |
Other Equity | -20 | -47 | -4 | -5 | -15 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 2,372 | 2,251 | 2,604 | 2,438 | 2,313 |
Total Liabilities & Shareholder's Equity | 2,980 | 2,690 | 3,106 | 2,917 | 2,822 |
Total Common Equity | 2,372 | 2,251 | 2,604 | 2,438 | 2,313 |
Shares Outstanding | 95.20 | 95.90 | 101.10 | 100.30 | 100.10 |
Book Value Per Share | 24.92 | 23.47 | 25.76 | 24.31 | 23.11 |
Fiscal Year End for Dolby Laboratories falls in the month of September.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 849 | 957 | 923 | 820 |
Receivables | NA | 293 | 262 | 267 | 283 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 38 | 36 | 32 | 30 |
Other Current Assets | NA | 271 | 233 | 247 | 329 |
Total Current Assets | NA | 1,451 | 1,488 | 1,469 | 1,463 |
Net Property & Equipment | NA | 479 | 482 | 502 | 508 |
Investments & Advances | NA | 93 | 98 | 98 | 101 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 207 | 202 | 210 | 204 |
Intangibles | NA | 570 | 576 | 604 | 469 |
Deposits & Other Assets | NA | 97 | 95 | 86 | 47 |
Total Assets | NA | 2,936 | 2,980 | 3,008 | 2,836 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 14 | 21 | 15 | 17 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 327 | 351 | 347 | 247 |
Income Taxes Payable | NA | 6 | 5 | 11 | 15 |
Other Current Liabilities | NA | 33 | 32 | 37 | 23 |
Total Current Liabilities | NA | 394 | 422 | 423 | 314 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 148 | 166 | 131 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 573 | 608 | 625 | 480 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 0 | 0 | 0 | 0 |
Retained Earnings | NA | 2,367 | 2,392 | 2,397 | 2,378 |
Other Equity | NA | -5 | -20 | -15 | -22 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 2,362 | 2,372 | 2,383 | 2,356 |
Total Liabilities & Shareholder's Equity | NA | 2,936 | 2,980 | 3,008 | 2,836 |
Total Common Equity | 0 | 2,362 | 2,372 | 2,383 | 2,356 |
Shares Outstanding | 95.50 | 95.50 | 95.20 | 95.60 | 95.50 |
Book Value Per Share | 0.00 | 24.74 | 24.92 | 24.92 | 24.67 |